C. Plöger

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

W. Klapper, M. Hallek, S. Stilgenbauer, 2016, The Lancet. Oncology.

Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital

A. Ho, M. Hensel, M. Witzens‐Harig, 2012, Annals of Hematology.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

W. Klapper, H. Döhner, J. Franklin, 2020, HemaSphere.

University of Southern Denmark Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) Kutsch,

W. Klapper, H. Döhner, J. Franklin, 2020 .

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

J. Hasford, T. Brümmendorf, D. Hossfeld, 2016, Leukemia.

Panitumumab in Combination With Preoperative Radiation Therapy in Patients With Locally Advanced RAS Wild-type Rectal Cancer: Results of the Multicenter Explorative Single-Arm Phase 2 Study NEORIT.

P. Kienle, U. Martens, S. Post, 2017, International journal of radiation oncology, biology, physics.

Panitumumab in Combination With Preoperative Radiation Therapy in Patients With Locally Advanced RAS Wild-type Rectal Cancer: Results of the Multicenter Explorative Single-Arm Phase 2 Study NEORIT.

P. Kienle, U. Martens, S. Post, 2017, International journal of radiation oncology, biology, physics.

The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG)

S. Stilgenbauer, T. Plesner, K. Kreuzer, 2024, HemaSphere.